Med Claims Compliance Corporation – Trademark Portfolio
Entity Type: 03
Med Claims Compliance Corporation holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include REMITONE. The owner is based in Austin, TX.
6500 River Pl Blvd., Bldg. 4, Ste. 350
6500 River Pl Blvd
Austin, TX 78730
Showing of trademarks Trademarks
Trademark Classifications
Med Claims Compliance Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Med Claims Compliance Corporation have?
Med Claims Compliance Corporation has 12 U.S. trademarks filed with the USPTO. Of these, 1 registered, 11 abandoned.
What trademark classes does Med Claims Compliance Corporation file in?
Med Claims Compliance Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 35 (Advertising & Business). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Med Claims Compliance Corporation's most well-known trademarks?
Med Claims Compliance Corporation's registered trademark portfolio includes well-known marks such as REMITONE. These are among 1 currently registered trademark in the portfolio.
What is Med Claims Compliance Corporation's trademark registration success rate?
Med Claims Compliance Corporation has a 8% trademark registration rate, with 1 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.